ETFs
Amplify ETFs Launches Amplify Weight Loss Drug & Treatment ETF (THNR)
Amplify ETFs
THNR invests in companies at the forefront of GLP-1 innovation
CHICAGO, May 21, 2024 (GLOBE NEWSWIRE) — Amplify ETFs announces the launch of the Amplify Weight Loss Drug & Treatment ETF (NYSE: THNR), an index ETF providing access to companies at the forefront of developing and commercializing GLP-1 care.
More than a billion people around the world are now clinically obese, drawing attention to the obesity epidemic as a critical public health problem.1 With increasing global attention to health and wellness, coupled with advances in medical treatments for weight management, THNR provides investors with targeted exposure to a rapidly evolving segment of the healthcare market.
Research projects that the GLP-1 market could reach $100 billion by 2030.2 The fund represents an opportunity to invest at the forefront of the development and production of weight-loss drugs, areas poised for growth. significant growth. “The launch of THNR aligns with our mission to provide innovative thematic investment solutions in new and existing market segments,” said Christian Magoon, CEO of Amplify ETFs.
GLP-1 drugs have been used to treat diabetes for over a decade. However, recent studies demonstrating a 10-20% reduction in body weight have led to a massive increase in demand.3 Pharmaceutical companies are now ramping up production to try to capture demand.
GLP-1 therapies offer hope beyond weight loss by potentially reducing cardiovascular risks, stroke, impulsive behavior, sleep apnea and kidney disease. Magoon notes the potentially significant impact that GLP-1s can have on overall public health: “We view THNR not just as an investment in high-growth pharmaceuticals, but as an investment in a healthier future. »
THNR tracks the VettaFi Weight Loss Drug & Treatment Index (the “Index”). The index includes companies classified as “drug manufacturers” and “facilitators.” The index includes a selection of companies, from those launching or testing GLP-1 agonist drugs to those enabling these crucial medical advances. Enablers are companies engaged in contract development and manufacturing, measurement and analysis, and/or distribution or administration of GLP-1 drugs.
The index allocates 70% to drug manufacturers and the remaining 30% to enablers, with weighted, float-adjusted market capitalization for each segment to provide broad exposure and balance. Companies in the drugmaker segment that are in commercial stage or phase 3 trials are capped at 15%, while those in early stages are limited to a 5% weighting. Facilitators are capped at 5%. The index is reconstituted and rebalanced quarterly to maintain alignment with the dynamic pharmaceutical landscape.
The story continues
Investors can learn more about THNR at AmplifyETFs.com/THNR.
About Amplify ETFs
Amplify ETFs, sponsored by Amplify Investments, has over $9 billion in assets across its ETF lineup (as of 3/31/2024). Amplify ETFs provide investment opportunities for investors seeking growth, income and risk management strategies across a range of actively managed and index-based ETFs. To learn more, visit AmplifyETFs.com.
Commercial contact:
Amplify ETFs
855-267-3837
info@amplifyetfs.com
Media contacts:
Gregory FCA for Amplify ETFs
Kerry Davis
610-228-2098
amplifyetfs@gregoryfca.com
1https://www.goldmansachs.com/intelligence/pages/anti-obesity-drug-market.html
2 https://www.who.int/news/item/01-03-2024-one-in-eight-people-are-now-living-with-obesity
3 https://www.morganstanley.com/im/en-us/individual-investor/insights/articles/glp1-the-weight-of-speculation.html
Consider the Fund’s investment objectives, risks, charges and expenses carefully before investing. This and other information can be found in the Fund’s statutory prospectuses and summaries, which can be obtained at AmplifyETFs.com. Read the prospectus carefully before investing.
Investing involves risks, including possible loss of capital. There can be no assurance that the investment objectives of the Fund will be achieved. The fund is new with limited operating history. Shares of any ETF are bought and sold at market price (not net asset value), may trade at a discount or premium to net asset value, and are not individually redeemed from the Fund. The Fund invests in securities included in its index regardless of their investment value and may be subject to tracking error: differences in trading timing, valuation, plus fees and expenses between the fund and the index .
A non-diversified fund may invest a greater portion of its assets in securities of individual issuers, which could result in greater fluctuations than a diversified fund. A narrowly focused portfolio concentrated in the pharmaceutical or healthcare industry may have higher volatility and be vulnerable to factors affecting it due to regulation, litigation, costs and competition. Small and/or mid-cap companies may be more vulnerable to adverse market or economic developments. Securities issued by foreign companies carry greater risks than securities of U.S. issuers.
Amplify Investments LLC serves as the Fund’s investment advisor. Penserra Capital Management LLC serves as investment sub-advisor to the Fund.
Amplify ETFs are distributed by Foreside Fund Services, LLC.
